Hypothyroidism Is a Risk Factor for New-Onset Diabetes: A Cohort Study

Diabetes Care

Volumn 38, Issue 9, 2015, Pages 1657-1664

  Gronich, Naomi ^a   Deftereos, Spyros N ^b   Lavi, Idit ^a   Persidis, Andreas S ^b   Abernethy, Darrell R ^c   Rennert, Gad ^a,d  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Biovista Inc   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RISK ASSESSMENT; RISK FACTOR; AGED; DIABETES MELLITUS, TYPE 2; ISRAEL; MIDDLE AGED; PROPENSITY SCORE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOTHYROIDISM; ISRAEL; MALE; MIDDLE AGED; PROPENSITY SCORE; RISK FACTORS;

EID: 84962345189     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2515     Document Type: Article

References (38)

1. Tudela CM, Casey BM, McIntire DD, Cunningham FG. Relationship of subclinical thyroid disease to the incidence of gestational diabetes. Obstet Gynecol 2012;119:983-988.
2. Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf) 2008;69:963-969.
3. Zocor Package Insert. Available from http://www.merck.com/product/usa/pi-circulars/z/zocor/zocor-pi.pdf. Accessed 5 June 2015.
4. Berta E, Harangi M, Zśiros N, Nagy EV, Paragh G, Bodor M. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. Pharmazie 2014;69:420-423.
5. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin- Associated myopathy. Int J Cardiol 2012; 159:169-176.
6. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-917.
7. Goldstein MR, Mascitelli L. Do statins cause diabetes? Curr Diab Rep 2013;13:381-390.
8. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012; 380:565-571.
9. Pletcher MJ, Hulley SB. Statin therapy in young adults: ready for prime time? J Am Coll Cardiol 2010;56:637-640.
10. Biovista. Technology. Available from http://biovista.com/technology. Accessed 5 June 2015.
11. Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip Rev Syst Biol Med 2011;3:323-334.
12. Andronis C, Sharma A, Virvilis V, Deftereos S, Persidis A. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011;12:357-368.
13. Clalit. Available from http://www.clalitglobal.co.il/en. Accessed 5 June 2015.
14. Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009;360:2528-2535.
15. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch InternMed 2007;167:1533-1538.
16. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008;167:492-499.
17. Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012;97:326-333.
18. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab 2006; 91:4930-4937.
19. Teixeira SS, Tamrakar AK, Goulart-Silva F, Serrano-Nascimento C, Klip A, Nunes MT. Triiodothyronine acutely stimulates glucose transport into L6 muscle cells without increasing surface GLUT4, GLUT1, or GLUT3. Thyroid 2012;22:747-754.
20. Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160:785-790.
21. Weinstein SP, O'Boyle E, Fisher M, Haber RS. Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. Endocrinology 1994;135: 649-654.
22. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007;92:491-496.
23. Ruhla S, Weickert MO, Arafat AM, et al. A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf) 2010;72: 696-701.
24. Kvetny J, Wilms L, Pedersen PL, Larsen J. Subclinical hypothyroidism affects mitochondrial function. Horm Metab Res 2010;42:324- 327.
25. Giudetti AM, Leo M, Siculella L, Gnoni GV. Hypothyroidism down-regulates mitochondrial citrate carrier activity and expression in rat liver. Biochim Biophys Acta 2006;1761:484-491.
26. Maity S, Kar D, De K, Chander V, Bandyopadhyay A. Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion. J Endocrinol 2013;217: 215-228.
27. Venditti P, Bari A, Di Stefano L, Di Meo S. Role of mitochondria in exercise-induced oxidative stress in skeletal muscle from hyperthyroid rats. Arch Biochem Biophys 2007;463:12-18.
28. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005;12:111-119.
29. Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 2013;61: 44-53.
30. Ma ZA, Zhao Z, Turk J. Mitochondrial dysfunction and b-cell failure in type 2 diabetes mellitus. Exp Diabetes Res 2012;2012:703538.
31. Gurzov EN, Eizirik DL. Bcl-2 proteins in diabetes: mitochondrial pathways of b-cell death and dysfunction. Trends Cell Biol 2011;21:424- 431.
32. Lu H, Koshkin V, Allister EM, Gyulkhandanyan AV, Wheeler MB. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 2010;59:448- 459.
33. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3- L1 adipocytes. FEBS Lett 2001;507:357-361.
34. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
35. Danaei G, Garćia Rodŕiguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: An analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013;36:1236-1240.
36. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172: 144-152.
37. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared withmoderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-2564.
38. Dormuth CR, Filion KB, Paterson JM, et al.; Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014;348:g3244.